SCHEMBL3001155

SCHEMBL3001155

CCC(c1ccccc1)N1CCC2(CC1)OCCc1c2cnn1-c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 2/20 0.47
▸ OPRD1 P41143 2/20 0.47
▸ OPRK1 P41145 2/20 0.47
▸ OPRL1 P41146 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003989 0.80 — —
SCHEMBL3003988 0.80 — —
SCHEMBL3001391 0.80 — —
SCHEMBL3003990 0.78 — —
SCHEMBL2997994 0.78 SIGMAR1 (0.60) —
SCHEMBL2998726 0.77 — —
SCHEMBL3008534 0.76 — —
SCHEMBL3001157 0.75 — —
SCHEMBL3008314 0.74 — —
SCHEMBL3003887 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144915-B1 SPIRO-PYRANO-PYRAZOLE DERIVATIVES ESTEVE LABOR DR (ES) 2014-03-19 — — EP disclosed
US-20100197714-A1 SPIRO-PYRANO-PYRAZOLE DERIVATIVES LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) 2010-08-05 — — US disclosed
EP-2144915-A1 SPIRO-PYRANO-PYRAZOLE DERIVATIVES Laboratorios Del. Dr. Esteve, S.A. (ES) 2010-01-20 — — EP disclosed
WO-2008125349-A1 SPIRO-PYRANO-PYRAZOLE DERIVATIVES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197714-A1 SPIRO-PYRANO-PYRAZOLE DERIVATIVES SIGMAR1, TMEM97, OPRD1 OPRM1 32/4885OPRD1 3/4885OPRK1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback